Efficacy and Safety Study of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions
Название протокола
Клинические исследование Myelodysplastic Syndromes: Luspatercept, Epoetin alfa - Реестр клинических исследований
